AEMD AETHLON MEDICAL INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 882291 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY28.3%
TTM EPS YoY137.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-136.8%
ROA-110.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.4%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $0 | $574,245 | $294,165 |
| R&D expense | $1.91M | $2.21M | $2.52M | $2.75M | $2.34M |
| SG&A expense | $2.70M | $3.24M | $3.90M | $4.48M | $3.46M |
| Operating income | -$7.29M | -$9.34M | -$12.64M | -$11.90M | -$10.42M |
| Interest expense | $14,372 | $10,109 | — | — | — |
| Pretax income | -$7.15M | -$13.39M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.15M | -$13.39M | -$12.21M | -$12.03M | -$10.42M |
| EBITDA | -$6.97M | -$9.00M | -$12.28M | -$11.66M | -$10.30M |
| EPS (basic) | -10.61 | -85.77 | -38.87 | -5.86 | -0.71 |
| EPS (diluted) | -10.61 | -85.77 | -38.87 | -5.86 | -0.71 |
| Weighted avg. shares (diluted) | 673,945 | 156,085 | 314,097 | 2.05M | 14.76M |
| Balance sheet | |||||
| Cash & equivalents | $5.03M | $5.60M | $5.53M | $14.62M | $17.16M |
| Receivables | — | — | — | $0 | $127,965 |
| Current assets | $5.57M | $5.95M | $6.23M | $15.09M | $18.16M |
| PP&E, net | $356,822 | $676,220 | $1.02M | $1.14M | $441,238 |
| Intangibles | $0 | $550 | $1,100 | $1,650 | $2,200 |
| Total assets | $6.33M | $7.36M | $8.25M | $17.51M | $19.42M |
| Current liabilities | $1.45M | $1.90M | $1.83M | $1.51M | $1.82M |
| Total liabilities | $1.45M | $2.24M | $2.48M | $2.44M | $2.43M |
| Shareholders' equity | $4.89M | $5.12M | $5.77M | $15.06M | $16.99M |
| Shares outstanding | 314,100 | 201,074 | 328,728 | 2.30M | 15.42M |
| Cash flow statement | |||||
| Operating cash flow | -$7.00M | -$7.65M | -$10.13M | -$10.51M | -$9.77M |
| Capital expenditure | $3,704 | $0 | $250,867 | $943,109 | $349,193 |
| Free cash flow | -$7.00M | -$7.65M | -$10.38M | -$11.45M | -$10.12M |
| Investing cash flow | -$3,704 | $0 | -$250,867 | -$943,109 | -$349,193 |
| Financing cash flow | $6.52M | $7.73M | $1.29M | $8.91M | $17.37M |
| Depreciation & amortization | $323,653 | $339,559 | $359,057 | $240,892 | $123,685 |
| Stock-based compensation | $278,547 | $415,234 | $1.22M | $1.05M | $750,621 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.